ArticleEuropean journal of nuclear medicine and molecular imaging2014
PET/MRI and PET/CT in follow-up of head and neck cancer patients.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Recent advances in PET/MR imaging for head and neck tumors: a systematic review of the last three years.La Radiologia medica · 2025Pooled it
- Diagnostic Performance of Whole-Body PET/MRI for Detecting Malignancies in Cancer Patients: A Meta-Analysis.PloS one · 2016Pooled it
- [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2016Trial
- Diagnostic Accuracy of PET/CT and Diffusion-weighted MRI in Detecting Residual Oropharyngeal Carcinoma after Chemoradiotherapy.Radiology. Imaging cancer · 2026Article
- Review
- Application ofDiagnostics (Basel, Switzerland) · 2025Article
- Positron Emission Tomography-Magnetic Resonance Imaging, a New Hybrid Imaging Modality for Dentomaxillofacial Malignancies-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Head and Neck Tumor Segmentation Using Pre-RT MRI Scans and Cascaded DualUNet.Head and Neck Tumor Segmentation for MR-Guided Applications : First MICCAI Challenge, HNTS-MRG 2024, held in conjunction with MICCAI 2024, Marrakesh, Morocco, October 17, 2024, proceedings · 2025Article
- The use of PET/MRI in radiotherapy.Insights into imaging · 2024Review
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.European journal of nuclear medicine and molecular imaging · 2023Article
- Diagnostic Accuracy ofContrast media & molecular imaging · 2022Observational
- Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma.Annals of nuclear medicine · 2021Article
- Value ofCancer management and research · 2021Article
- Are Gadolinium-Enhanced MR Sequences Needed in SimultaneousAJNR. American journal of neuroradiology · 2020Article
- Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study toCancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Inter- and Intrareader Agreement of NI-RADS in the Interpretation of Surveillance Contrast-Enhanced CT after Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.AJNR. American journal of neuroradiology · 2020Article
- Preliminary clinical results for PET/MR compared with PET/CT in patients with nasopharyngeal carcinoma.Oncology reports · 2020Article
- Histometabolic Tumor Imaging of Hypoxia in Oral Cancer: Clinicopathological Correlation for Prediction of an Aggressive Phenotype.Frontiers in oncology · 2020Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron emission tomography (PET)/MRI combines the functional ability of PET and the high soft tissue contrast of MRI. The aim of this study was to assess contrast-enhanced (ce)PET/MRI compared to cePET/CT in patients with suspected recurrence of head and neck cancer (HNC).
methodsEighty-seven patients underwent sequential cePET/CT and cePET/MRI using a trimodality PET/CT-MRI set-up. Diagnostic accuracy for the detection of recurrent HNC was evaluated using cePET/CT and cePET/MRI. Furthermore, image quality, presence of unclear (18)F-fluorodeoxy-D-glucose (FDG) findings of uncertain significance and the diagnostic advantages of use of gadolinium contrast enhancement were analysed.
resultscePET/MRI showed no statistically significant difference in diagnostic accuracy compared to cePET/CT (91.5 vs 90.6%). Artefacts' grade was similar in both methods, but their location was different. cePET/CT artefacts were primarily located in the suprahyoid area, while on cePET/MRI, artefacts were more equally distributed among the supra and infrahyoid neck regions. cePET/MRI and cePET/CT showed 34 unclear FDG findings; of those 11 could be solved by cePET/MRI and 5 by cePET/CT. The use of gadolinium in PET/MRI did not yield higher diagnostic accuracy, but helped to better define tumour margins in 6.9% of patients.
conclusionOur data suggest that cePET/MRI may be superior compared to cePET/CT to specify unclear FDG uptake related to possible tumour recurrence in follow-up of patients after HNC. It seems to be the modality of choice for the evaluation of the oropharynx and the oral cavity because of a higher incidence of artefacts in cePET/CT in this area mainly due to dental implants. However, overall there is no statistically significant difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.